Oftentimes, we forget how valuable our FDA is because we are used to only seeing the sensational critiques in the media: unwarranted drug approvals, inadequate surveillance, negligent public alerts or inappropriate industry influence.
Thank you Advocates! FDA Issues Draft Guidance for Biosimilar Naming: A Proposed Rule that Designates Official Names and Proper Names for Certain Biological Products Your efforts are making a difference. GHLF is pleased to share that the Food and Drug Administration (FDA) released a draft guidance requiring biological products licensed under the Public Health Service […]
GHLF applauds our CreakyJoints community for taking action!
On July 24th, the Texas Pharmaceutical and Therapeutics (P&T) Committee, a part of the Texas Health and Human Services Commission, convened to review a number of different medications and medication classes for entry onto their Preferred Drug List (PDL) of the Texas Medicaid Formulary. A medication to alleviate symptoms of opioid-induced constipation (OIC) was one […]
Assemblywoman Jaffee provided our listeners with some important advice about the power of the patient perspective. Listen to what she had to say: